Close Menu

NEW YORK – 23andMe has laid off approximately 100 employees, about 14 percent of its workforce, the direct-to-consumer genetic testing company confirmed on Thursday.

According to a spokesperson, the layoffs occurred across the company's consumer business, which is being restructured, but did not affect its therapeutics business.

Going forward, 23andMe will focus its activities on its core businesses, consumer genomics and therapeutics, and plans to scale back on non-core activities, such as clinical trials, the spokesperson said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.